181 related articles for article (PubMed ID: 30695819)
1. Systematic review with meta-analysis: the critical role of dermatological events in patients with hepatocellular carcinoma treated with sorafenib.
Díaz-González Á; Sanduzzi-Zamparelli M; Sapena V; Torres F; LLarch N; Iserte G; Forner A; da Fonseca L; Ríos J; Bruix J; Reig M
Aliment Pharmacol Ther; 2019 Mar; 49(5):482-491. PubMed ID: 30695819
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib as first-line therapy in patients with advanced Child-Pugh B hepatocellular carcinoma-a meta-analysis.
McNamara MG; Slagter AE; Nuttall C; Frizziero M; Pihlak R; Lamarca A; Tariq N; Valle JW; Hubner RA; Knox JJ; Amir E
Eur J Cancer; 2018 Dec; 105():1-9. PubMed ID: 30384012
[TBL] [Abstract][Full Text] [Related]
3. Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib.
Reig M; Torres F; Rodriguez-Lope C; Forner A; LLarch N; Rimola J; Darnell A; Ríos J; Ayuso C; Bruix J
J Hepatol; 2014 Aug; 61(2):318-24. PubMed ID: 24703956
[TBL] [Abstract][Full Text] [Related]
4. Complete response under sorafenib in patients with hepatocellular carcinoma: Relationship with dermatologic adverse events.
Rimola J; Díaz-González Á; Darnell A; Varela M; Pons F; Hernandez-Guerra M; Delgado M; Castroagudin J; Matilla A; Sangro B; Rodriguez de Lope C; Sala M; Gonzalez C; Huertas C; Minguez B; Ayuso C; Bruix J; Reig M
Hepatology; 2018 Feb; 67(2):612-622. PubMed ID: 28898447
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Radioembolization and Sorafenib for the Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Systematic Review and Meta-Analysis of Safety and Efficacy.
Kim PH; Choi SH; Kim JH; Park SH
Korean J Radiol; 2019 Mar; 20(3):385-398. PubMed ID: 30799569
[TBL] [Abstract][Full Text] [Related]
6. A meta-analysis of the efficacy and safety of adjuvant sorafenib for hepatocellular carcinoma after resection.
Huang S; Li D; Zhuang L; Sun L; Wu J
World J Surg Oncol; 2021 Jun; 19(1):168. PubMed ID: 34112190
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
Vilgrain V; Pereira H; Assenat E; Guiu B; Ilonca AD; Pageaux GP; Sibert A; Bouattour M; Lebtahi R; Allaham W; Barraud H; Laurent V; Mathias E; Bronowicki JP; Tasu JP; Perdrisot R; Silvain C; Gerolami R; Mundler O; Seitz JF; Vidal V; Aubé C; Oberti F; Couturier O; Brenot-Rossi I; Raoul JL; Sarran A; Costentin C; Itti E; Luciani A; Adam R; Lewin M; Samuel D; Ronot M; Dinut A; Castera L; Chatellier G;
Lancet Oncol; 2017 Dec; 18(12):1624-1636. PubMed ID: 29107679
[TBL] [Abstract][Full Text] [Related]
8. Sorafenib versus hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: a systematic review and meta-analysis.
Zhuang BW; Li W; Xie XH; Hu HT; Lu MD; Xie XY
Jpn J Clin Oncol; 2019 Sep; 49(9):845-855. PubMed ID: 31063184
[TBL] [Abstract][Full Text] [Related]
9. Increased cumulative doses and appearance of hand-foot skin reaction prolonged progression free survival in sorafenib-treated advanced hepatocellular carcinoma patients.
Chang WT; Lu SN; Rau KM; Huang CS; Lee KT
Kaohsiung J Med Sci; 2018 Jul; 34(7):391-399. PubMed ID: 30063012
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of cytotoxic chemotherapy in hepatocellular carcinoma after first-line treatment with sorafenib.
da Fonseca LG; Marta GN; Braghiroli MIFM; Chagas AL; Carrilho FJ; Hoff PM; Sabbaga J
BMC Cancer; 2018 Dec; 18(1):1250. PubMed ID: 30545331
[TBL] [Abstract][Full Text] [Related]
11. Fatal adverse events with molecular targeted agents in the treatment of advanced hepatocellular carcinoma: a meta-analysis of randomized controlled trials.
Li X; Wan J; Wu Z; Tu J; Hu Y; Wu S; Lou L
Drug Des Devel Ther; 2018; 12():3043-3049. PubMed ID: 30271119
[TBL] [Abstract][Full Text] [Related]
12. Hand-foot-skin reaction of grade ≥ 2 within sixty days as the optimal clinical marker best help predict survival in sorafenib therapy for HCC.
Wang E; Xia D; Bai W; Wang Z; Wang Q; Liu L; Wang W; Yuan J; Li X; Chen H; Lv Y; Niu J; He C; Guo W; Yin Z; Luo B; Han N; Wang Z; Yu T; Yuan X; Li K; Tie J; Li C; Cai H; Xia J; Fan D; Han G
Invest New Drugs; 2019 Jun; 37(3):401-414. PubMed ID: 30019101
[TBL] [Abstract][Full Text] [Related]
13. Effect of urea cream on sorafenib-associated hand-foot skin reaction in patients with hepatocellular carcinoma: A multicenter, randomised, double-blind controlled study.
Lee YS; Jung YK; Kim JH; Cho SB; Kim DY; Kim MY; Kim HJ; Seo YS; Yoon KT; Hong YM; Lee JH; Lee HW; Yim HJ; Jang BK; Jang ES; Jang JY; Hwang SY
Eur J Cancer; 2020 Nov; 140():19-27. PubMed ID: 33039810
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score.
Hollebecque A; Cattan S; Romano O; Sergent G; Mourad A; Louvet A; Dharancy S; Boleslawski E; Truant S; Pruvot FR; Hebbar M; Ernst O; Mathurin P
Aliment Pharmacol Ther; 2011 Nov; 34(10):1193-201. PubMed ID: 21958438
[TBL] [Abstract][Full Text] [Related]
15. Survival of patients treated with sorafenib for hepatocellular carcinoma recurrence after liver transplantation: a systematic review and meta-analysis.
Mancuso A; Mazzola A; Cabibbo G; Perricone G; Enea M; Galvano A; Zavaglia C; Belli L; Cammà C
Dig Liver Dis; 2015 Apr; 47(4):324-30. PubMed ID: 25641331
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Bruix J; Takayama T; Mazzaferro V; Chau GY; Yang J; Kudo M; Cai J; Poon RT; Han KH; Tak WY; Lee HC; Song T; Roayaie S; Bolondi L; Lee KS; Makuuchi M; Souza F; Berre MA; Meinhardt G; Llovet JM;
Lancet Oncol; 2015 Oct; 16(13):1344-54. PubMed ID: 26361969
[TBL] [Abstract][Full Text] [Related]
17. Are we SHARP enough? The importance of adequate patient selection in sorafenib treatment for hepatocellular carcinoma.
Labeur TA; Ten Cate DWG; Bart Takkenberg R; Azahaf H; van Oijen MGH; van Delden OM; de Man RA; van Vugt JLA; IJzermans JNM; Eskens FALM; Klümpen HJ
Acta Oncol; 2018 Nov; 57(11):1467-1474. PubMed ID: 29943624
[TBL] [Abstract][Full Text] [Related]
18. Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients.
Tovoli F; Ielasi L; Casadei-Gardini A; Granito A; Foschi FG; Rovesti G; Negrini G; Orsi G; Renzulli M; Piscaglia F
J Hepatol; 2019 Dec; 71(6):1175-1183. PubMed ID: 31449860
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib in treatment of patients with advanced hepatocellular carcinoma: a systematic review.
Zhang X; Yang XR; Huang XW; Wang WM; Shi RY; Xu Y; Wang Z; Qiu SJ; Fan J; Zhou J
Hepatobiliary Pancreat Dis Int; 2012 Oct; 11(5):458-66. PubMed ID: 23060390
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of hepatocellular carcinoma patients treated with sorafenib: a meta-analysis of Phase III trials.
Cabibbo G; Cucchetti A; Cammà C; Casadei-Gardini A; Celsa C; Emanuele Maria Rizzo G; Johnson P; Ercolani G
Future Oncol; 2019 Oct; 15(29):3411-3422. PubMed ID: 31588789
[No Abstract] [Full Text] [Related]
[Next] [New Search]